Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,781 total articles
Conagra (CAG) trades like a beaten-up consumer staple with an 8.9% yield, solid free cash flow ($842M) and valuation multiples that scream recovery potential (P/S 0.68, EV/EBITDA 8.6). I am upgrading Conagra to a buy and will build a position around $15.77, with a $22 target over the next 180 trading days and a $14.50 protective stop. This is a val…
Embraer’s roughly $50 billion in contracted and optioned backlog is the clearest near-term anchor for revenue and cash flow through FY 2026. Delivery cadence improvement, services growth and defense awards can drive upside. Trade plan: enter at $13.50, target $18.00, stop $11.00; horizon: long term (180 trading days).
Expedia (EXPE) is trading on attractive cash-flow multiples and benefits from margin leverage and aggressive buybacks. We recommend a swing trade re-entry at $229.02, targeting $260 then $300 with a $210 stop. Key drivers are operating leverage, $3.11B in free cash flow, and an EV/EBITDA of ~9.5 that leaves room for upside if margins normalize.
Petrobras is trading cheaply relative to earnings with a $129B market cap, a P/E near 6.7 and a 5.2% dividend yield. Momentum is pushing the stock toward and just above its 52-week high; this trade recommends adding on strength with a clear entry at $21.50, a stop at $20.00, and a mid-term target of $24.00 (45 trading days). We size risk conservati…
GigaCloud (GCT) has quietly built a profitable B2B marketplace for large-parcel merchandise and is trading at an attractive multiple versus its growth and cash generation. Backed by $182.8M in free cash flow, a P/E near 12, and an EV/EBITDA of 8.4, the stock offers a clear swing-trade setup: entry $45.00, stop $41.00, target $55.00 over ~45 trading…
Radian Group's $1.7B Inigo acquisition and planned repositioning into specialty insurance materially change the company's risk/reward. At $33.97 the stock trades at ~8x earnings and ~1x book with a 3% yield, leaving room for multiple expansion if management executes. This trade targets a re-rating toward the mid-$30s while preserving capital with a…
Shopify's valuation looks rich on traditional multiples today, but an accelerating shift to AI-first commerce tools and higher-value merchant services (recommenders, automated personalization, intelligent fulfillment) creates a path for revenue and margin re-acceleration. This trade idea buys that re-rate: entry $118.81, stop $102.00, target $165.0…
Oracle's hotly debated round of layoffs and leadership changes are painful but pragmatic moves that should improve margins on a $553B contract backlog and heavy cloud demand. The pullback has opened a disciplined buy-the-dip opportunity: mid-term swing trade sized to tolerance, with a clear stop to respect leverage and litigation risk.
BE Semiconductor (BESIY) is an underfollowed supplier of semiconductor assembly equipment sitting at the intersection of surging AI demand and constrained packaging capacity. Technical momentum, heavy short interest and a compact float make this a trade worth considering for disciplined long exposure over the next 180 trading days. Valuation is ric…
Cipher Digital (CIFR) has moved from pure-play Bitcoin mining toward large-scale AI infrastructure, signing multi-billion-dollar, long-dated deals and closing $2.0B in secured notes to finish its flagship Black Pearl campus. The stock trades at $13.35 with a $5.4B market cap and expensive headline multiples, but the combination of long-term hypersc…
The Buckle (BKE) remains a well-run, cash-rich apparel retailer with a $2.6B market cap, strong returns and no debt. Those fundamentals, however, could fail to insulate the stock from a near-term consumer slowdown and rate-driven sentiment shifts. We lay out a mid-term (45 trading days) short trade: entry $50.97, target $44.00, stop $55.50 — size i…
Cardiff Oncology’s shares look oversold after the market largely ignored a 64% objective response rate in first-line RAS-mutated mCRC. With a sub-$110M market cap, recent presentations and a tight float loaded with short interest, this is an actionable event-driven long with defined risk control.
After closing the Golden Ocean merger and refreshing its fleet, CMB.TECH sits on a fleet valued at $11.1B and a market cap around $4.14B. The stock traded at $13.07 as of the latest session; technicals show constructive momentum and short interest has been falling. This is a tactical long for investors who believe the market will reward scale and d…
Pan American Silver (PAAS) offers a defined swing trade in today’s extreme commodity volatility: buy near $55.95 with a stop at $52.25 and a target at $69.99. The setup leans on strong liquidity metrics, exploration upside at La Colorada, and a market still pricing in upside for silver. Keep position sizing tight—this is a medium-risk play that wor…
Iovance (IOVA) is a high-risk, high-reward name: approved autologous TIL therapy (Amtagvi/lifileucel) is producing meaningful revenue growth and best-in-class real-world response rates, while the stock is depressed near $3.30 with heavy short interest. We favor buying a measured pullback for multi‑quarter upside, with disciplined risk controls.
Fox Factory (FOXF) is trading well below its 52-week high after a difficult earnings stretch and a hit to reported EPS. The company's niche in performance suspension, OEM partnerships, and growing UTV/aftermarket markets — plus recent brand deals — argue for a multi-quarter recovery. Buy on weakness with a disciplined stop and a 180-trading-day tar…
Apogee (APOG) trades at an attractive multiple relative to cash flow and sales with a market cap of roughly $717M, EV/EBITDA ~8 and free cash flow of $67M. Recent weakness reflects cyclical headwinds and restructuring charges, but improving margins from cost-cutting and a 3%+ dividend make a measured long trade compelling. Entry $33.33, stop $30.50…
Guardant Health is trading off a recent high but has tangible catalysts — including a new FDA companion diagnostic approval and expanding market tailwinds for liquid biopsy — that justify a tactical long. This trade plan targets a mid-term rebound to $110 while capping downside at $82, using the current weakness as an entry.
NIO combines a sharp recovery in deliveries, a first quarterly profit, and improving technicals with elevated short interest. I favor a mid-term long trade at current levels ($6.24) to capture upside from continued delivery momentum and potential short-covering, while keeping a disciplined $5.00 stop to limit downside.
<p>Black Stone Minerals (BSM) offers a mix of high current yield and free-cash-flow support that can outperform if continued data center expansion lifts regional power and fuel demand. At $14.47 and a market cap near $3.07B, the units trade at a modest P/E and attractive yield that give a clear risk/reward for a long trade over the next 180 trading…
Alphabet looks expensive on surface multiples but still generates enormous free cash flow, a fortress balance sheet, and multiple 2026 catalysts (AI product rollouts, SpaceX stake, Cloud momentum). This trade idea lays out a long position with an entry at the current market price, a conservative stop, and a target near the prior 52-week peak — size…
Asure (ASUR) is a profitable trade idea today despite headline risks. At $8.55 the stock sits below its 52-week high but shows improving fundamentals: recurring revenue gains after the Lathem Time acquisition, a string of strategic hires and partnerships, and free cash flow of $21.4M that supports a near 9% FCF yield on a ~$242M market cap. I recom…
A favorable professional review of Geely’s newest model crystallizes what many investors already suspected: Chinese OEMs can build competitive, cost-effective EVs that will appeal to American buyers. That structural shift creates a tactical long trade on Geely’s ADR (GELYY) with defined entry, stop and targets over a mid-term horizon.
Praxis Precision Medicines reported compelling Phase 1/2 EMBRAVE Part A results for elsunersen (PRAX-222) and has multiple late-stage programs plus fresh capital and high-conviction institutional investors. With a market cap near $8.64B, a tight float, and clear regulatory catalysts ahead, we rate PRAX a Strong Buy and outline an actionable trade p…
Synchrony Financial (SYF) is trading at a single-digit P/E, strong ROE, and an EV/EBITDA that implies limited macro expectations. The recent pullback tied to sector-policy headlines creates a controlled entry at $69.27 with a $82 target over a 180-trading-day horizon and a $62 stop. This is an upgrade to buy based on valuation, improving consumer c…
